Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 650
Summary
- Conditions
- Brain Edema
- Stroke Acute
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
This study, previously posted by Remedy Pharmaceuticals, Inc., has transitioned to Biogen.
This study, previously posted by Remedy Pharmaceuticals, Inc., has transitioned to Biogen.
Tracking Information
- NCT #
- NCT02864953
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Biogen